Skip to main content
SpringerLink
Log in

Pulmonary Involvement in Systemic Sclerosis

  • Therapy In Practice
  • Published:
Treatments in Respiratory Medicine

Abstract

Scleroderma, also known as progressive systemic sclerosis (SSc), is a multisystem autoimmune disorder characterized by inflammation and fibrosis involving the skin as well as internal organs such as the vasculature, esophagus, and the respiratory tract. Pulmonary involvement consists most often of interstitial fibrosis and pulmonary vascular disease leading to pulmonary arterial hypertension (PAH). Bronchiectasis is an uncommon pulmonary manifestation of systemic sclerosis. Pulmonary hemorrhage with acute renal failure and diffuse alveolar hemorrhage in the absence of a history of renal involvement or penicillamine intake have rarely been reported in patients with systemic sclerosis.

On high resolution CT, evidence of interstitial disease is seen in approximately 90% of patients, the main findings being a fine reticular pattern involving the subpleural regions of the lower lobe. Other common findings include ground-glass opacities, honeycombing, and parenchymal micronodules. The most distinctive pulmonary histologic findings in patients with scleroderma are the vascular changes found in PAH in the absence of significant interstitial fibrosis.

There is no strong evidence that any drug alters the course of the two main types of lung disease in systemic sclerosis. This apparent failure of therapy may reflect the fact that pulmonary involvement is usually identified at an established or late stage. It has been suggested that, for fibrosing alveolitis, corticosteroids are most effective if given in combination with cyclophosphamide. In some patients with SSc, PAH has been considered as a major cause of morbidity and mortality. Centrally infused prostacyclin (epoprostenol) and its subcutaneously infused analog treprostinil improve hemodynamics, as well as the quality of life and survival in these patients. Iloprost has also shown a positive effect on PAH in SSc patients. More recently, bosentan, an endothelin receptor antagonist, has proved effective in controlling PAH after 6 months’ treatment. Sildenafil has been used as a selective pulmonary vasodilator in SSc patients with isolated PAH. This drug decreased mean pulmonary artery pressure and pulmonary vascular resistance, and increased cardiac output, with much improvement of the physical condition of the patients. Lung transplant can be considered as a last option.

Clinicians must be aware of the possibility of lung disease in patients with SSc so that it can be treated as early as possible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Steen V, Owens G, Fino G, et al. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985; 28: 759–67

    Article  PubMed  CAS  Google Scholar 

  2. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003; 62: 97–9

    Article  PubMed  CAS  Google Scholar 

  3. Weaver AL, Divertie MB, Titus JL. Pulmonary scleroderma. Dis Chest 1968; 54: 490–8

    Article  PubMed  CAS  Google Scholar 

  4. Rossi GA, Bitterman PB, Rennard SI, et al. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Respir Dis 1985; 124: 612–7

    Google Scholar 

  5. Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991; 144: 706–13

    Article  PubMed  CAS  Google Scholar 

  6. Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003; 62: 146–50

    Article  PubMed  CAS  Google Scholar 

  7. Scully R, Mark E, McNeely W, et al. Case records of the Massachusetts General Hospital. N Engl J Med 1989; 320: 1333–40

    Article  Google Scholar 

  8. Gindzienska-Sieskiewicz E, Kowal-Bielecka O, Kita J, et al. The occurrence of pulmonary hypertension in patients with systemic sclerosis hospitalized in the department of rheumatology and internal medical University of Bialystok in years 2003–2004. Rocz Akad Med Bialymst 2005; 50: 297–300

    PubMed  Google Scholar 

  9. Salerni R, Rodnan GP, Leon DF, et al. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977; 68: 394–9

    Google Scholar 

  10. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947–54

    PubMed  CAS  Google Scholar 

  11. Jacobsen S, Halberg P, Ullman S, et al. A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin Rheumatol 1997; 16: 384–90

    Article  PubMed  CAS  Google Scholar 

  12. Highland KB, Silver RM. Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study. Curr Rheumatol Rep 2005; 7(2): 135–41

    Article  PubMed  Google Scholar 

  13. Du Bois RM. The genetic predisposition to interstitial lung disease. Chest 2002; 121: 14–20

    Article  Google Scholar 

  14. Dziankowska-Bartkowiak B, Waszczykowska E, Luczynska M, et al. Serum levels of tissue inhibitor of metalloproteinases 2 in systemic sclerosis: a preliminary study. Med Sci Monit 2002; 8(2): 108–12

    Google Scholar 

  15. Mattila L, Airola K, Ahonen M, et al. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 1998; 110: 416–21

    Article  PubMed  CAS  Google Scholar 

  16. Beon M, Harley RA, Wessels A, et al. Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin Exp Rheumatol 2004; 22(6): 733–42

    PubMed  CAS  Google Scholar 

  17. Wallaert B, Hatron PY, Grosbois JM, et al. Subclinical pulmonary involvement in connective tissue diseases assessed by bronchoalveolar lavage: relationship between alveolitis and subsequent changes in lung function. Am Rev Respir Dis 1986; 133: 574–80

    PubMed  CAS  Google Scholar 

  18. Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis: relationship of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1982; 124: 1–9

    Google Scholar 

  19. Steen VD, Graham G, Conte C, et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 35: 765–70

    Article  PubMed  CAS  Google Scholar 

  20. Alton E, Turner-Warwick M. Lung involvement in scleroderma. In: Jayson MIV, Black CM, eds. Systemic sclerosis: scleroderma. London: Wiley, 1988: 181–205

    Google Scholar 

  21. Watters LC, King TE, Schwarz MI, et al. A clinical, radiological, physiological scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133: 97–103

    PubMed  CAS  Google Scholar 

  22. Eaton T, Young P, Milne D, et al. Six minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Resp Crit Care Med 2005; 171: 1150–7

    Article  PubMed  Google Scholar 

  23. Witt Ch, Dörner T, Hiepe F, et al. Diagnosis of alveolitis in interstitial lung manifestation in connective tissue diseases: importance of late inspiratory crackles, 67 gallium scan and bronchoalveolar lavage. Lupus 1996; 5: 606–12

    Article  PubMed  CAS  Google Scholar 

  24. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis. Arthritis Rheum 1997; 40: 1229–36

    PubMed  CAS  Google Scholar 

  25. Witt C, Borges AC, John M, et al. Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis 1999; 58: 635–40

    Article  PubMed  CAS  Google Scholar 

  26. Silver RM. Scleroderma: clinical problems. The lungs. Rheum Dis Clin North Am 1996; 22: 825–40

    Article  CAS  Google Scholar 

  27. Silver RM, Scott Miller K, Kinsella MB, et al. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88: 470–6

    Article  PubMed  CAS  Google Scholar 

  28. Behr J, Vogelmeier C, Beinert T, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996; 154: 400–6

    PubMed  CAS  Google Scholar 

  29. Clements PJ, Goldin JG, Kleerup EC, et al. Regional differences in bronchoalveolar lavage and thoracic high resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum. 2004; 50(6): 1909–17

    Article  PubMed  Google Scholar 

  30. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20(5): 838–44

    PubMed  CAS  Google Scholar 

  31. Akesson A, Scheja A, Lundin A, et al. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37: 729–35

    Article  PubMed  CAS  Google Scholar 

  32. Varai G, Earle L, Jimenez SA, et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998; 25: 1325–9

    PubMed  CAS  Google Scholar 

  33. Davas EM, Peppas C, Maragou M, et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18: 455–61

    Article  PubMed  CAS  Google Scholar 

  34. Pakas I, Ioannidis JP, Malagari K, et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29: 298–304

    PubMed  CAS  Google Scholar 

  35. Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731–6

    PubMed  CAS  Google Scholar 

  36. Griffiths B, Miles S, Hilary M, et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29: 2371–8

    PubMed  CAS  Google Scholar 

  37. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998; 41: 1215–20

    Article  PubMed  CAS  Google Scholar 

  38. Kowal-Bielecka O, Kowal K, Rojewska J, et al. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations. Ann Rheum Dis 2005; 64: 1343–6

    Article  PubMed  CAS  Google Scholar 

  39. Airo P, Danieli E, Parrinello G, et al. Intravenous cyclophosphamide therapy for systemic sclerosis: a single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004; 22(5): 551–2

    Google Scholar 

  40. Beretta L, Caronni M, Raimondi M, et al. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol. Epub 2006 Apr 14

  41. Steen VD, Medsger TA, Rodnan GP. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma). Ann Intern Med 1982; 97: 652–9

    PubMed  CAS  Google Scholar 

  42. Calguneri M, Apras S, Ozbalkan Z, et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 2003; 22: 289–94

    Article  PubMed  CAS  Google Scholar 

  43. De Clerck LS, Dequeker J, Francx L, et al. D-Penicillamine therapy and interstitial lung disease in scleroderma: a long term followup study. Arthritis Rheum 1987; 30: 643–50

    Article  PubMed  Google Scholar 

  44. Akesson A, Blom-Bulow B, Scheja A, et al. Long-term evaluation of penicillamine or cyclofenil in systemic sclerosis: results from a two-year randomized study. Scand J Rheumatol 1992; 21(5): 238–44

    Article  PubMed  CAS  Google Scholar 

  45. Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis: results of a forty eight week open safety study in ten patients. Arthritis Rheum 1993; 36(1): 75–83

    Article  PubMed  CAS  Google Scholar 

  46. Pope Je, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44(6): 1351–8

    Article  PubMed  CAS  Google Scholar 

  47. Sontag SJ, O’Connell S, Khandelwal S, et al. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 1990; 99: 613–20

    PubMed  CAS  Google Scholar 

  48. Mansfield LE. Gastroesophageal reflux and diseases of the respiratory tract: A review. J Asthma 1989; 26: 271–8

    Article  PubMed  CAS  Google Scholar 

  49. Mansfield LE, Hameister HH, Spaulding HS, et al. The role of the vagus nerve in airway narrowing caused by intraesophageal hydrochloric acid provocation and esophageal distention. Ann Allergy 1981; 47: 431–4

    PubMed  CAS  Google Scholar 

  50. Tuchman DN, Boyle JT, Pack AI, et al. Comparison of airway responses following tracheal or esophageal acidification in the cat. Gastroenterology 1984; 87: 872–81

    PubMed  CAS  Google Scholar 

  51. Mansfield LE, Stein MR. Gastroesophageal reflux and asthma: a possible reflex mechanism. Ann Allergy 1978; 41: 224–6

    PubMed  CAS  Google Scholar 

  52. Pack AI. Acid: a nocturnal bronchoconstrictor [editorial]? Am Rev Respir Dis 1990; 141: 1391–2

    PubMed  CAS  Google Scholar 

  53. Larrain A, Carrasco E, Galleguillos F, et al. Medical and surgical treatment of nonallergic asthma associated with gastroesophageal reflux. Chest 1991; 99: 1330–5

    Article  PubMed  CAS  Google Scholar 

  54. Perrin-Fayolle M, Gormand F, Braillon G, et al. Long-term results of surgical treatment for gastroesophageal reflux in asthmatic patients. Chest 1989; 96: 40–5

    Article  PubMed  CAS  Google Scholar 

  55. Johnson DA, Drane WE, Curran J, et al. Pulmonary disease in progressive systemic sclerosis: a complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989; 149: 589–93

    Article  PubMed  CAS  Google Scholar 

  56. Moran TJ. Experimental aspiration pneumonia. Arch Pathol 1955; 60: 122–9

    CAS  Google Scholar 

  57. Chernow B, Johnson LF, Janowitz WR, et al. Pulmonary aspiration as a consequence of gastroesophageal reflux: a diagnostic approach. Dig Dis Sci 1979; 24: 839–44

    Article  PubMed  CAS  Google Scholar 

  58. Troshinsky MB, Kane GC, Varga J, et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 1994; 121: 6–19

    PubMed  CAS  Google Scholar 

  59. Henry DA. Pulmonary cysts in progressive systemic sclerosis (scleroderma). Rev Interam Radiol 1980; 5(4): 113–6

    PubMed  CAS  Google Scholar 

  60. Bar J, Ehrenfeld M, Rozenman J, et al. Pulmonary-renal syndrome in systemic sclerosis. Semin Arthritis Rheum 2001; 30(6): 403–10

    Article  PubMed  CAS  Google Scholar 

  61. Yamada T, Nakajima H, Tanaka E, et al. Case of systemic sclerosis presenting with alveolar hemorrhage and positive anti-neutrophil cytoplasmic myeloperoxidase antibody (MPO-ANCA) without pathological renal involvement. Ryumachi 2003; 43(4): 690–5

    PubMed  Google Scholar 

  62. Lavie F, Rozenberg S, Coutaux A, et al. Bronchiectasis in a patient with CREST syndrome. Joint Bone Spine 2002; 69(5): 515–8

    Article  PubMed  Google Scholar 

  63. Andonopoulos AP, Yarmenitis S, Georgiou P, et al. Bronchiectasis in systemic sclerosis: a study using high resolution computed tomography. Clin Exp Rheumatol 2001; 19(2): 187–90

    PubMed  CAS  Google Scholar 

  64. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515–23

    Article  PubMed  CAS  Google Scholar 

  65. Galei N, Torbicki A, Robyn B, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Europ Heart J 2006; 25(24): 2243–78

    Google Scholar 

  66. Steen VD, Owens GR, Fino GJ, et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992; 28: 759–67

    Article  Google Scholar 

  67. Kharitonov SA, Cailes JB, Black CM, et al. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997; 52: 1051–5

    Article  PubMed  CAS  Google Scholar 

  68. Ihn H, Sato S, Fujimoto M, et al. Measurement of anticardiolipin antibodies by ELISA using β2-glycoprotein I (β2-GPI) in systemic sclerosis. Clin Exp Immunol 1996; 37: 1188–92

    Google Scholar 

  69. Jinnin H, Ihn K, Yamane Y, et al. Plasma plasmin-2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension. Rheumatology 2003; 42: 240–3

    Article  PubMed  CAS  Google Scholar 

  70. Kon OM, Daniil Z, Black CM, et al. Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. Eur RespirJ 1999; 13(1): 133–6

    Article  CAS  Google Scholar 

  71. Yamane K, Ihn H, Asano Y, et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology 2000; 39: 1269–71

    Article  PubMed  CAS  Google Scholar 

  72. Rich S, Kauffman E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76–81

    Article  PubMed  CAS  Google Scholar 

  73. Seibold JR, Molony RR, Turkevich D, et al. Acute hemodynamic effects of ketanserin in pulmonary hypertension secondary to systemic sclerosis. J Rheumatol 1987; 14: 519–24

    PubMed  CAS  Google Scholar 

  74. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409–15

    PubMed  CAS  Google Scholar 

  75. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997 Aug; 30(2): 343–9

    Article  PubMed  CAS  Google Scholar 

  76. Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998 Aug; 80(2): 151–5

    PubMed  CAS  Google Scholar 

  77. Cao TS, Yuan LJ, Duan YY, et al. Clinical study on long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol infusion [in Chinese]. Zhonghua Nei Ke Za Zhi 2003; 42(2): 106–9

    PubMed  Google Scholar 

  78. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002 Aug 21; 40(4): 780–8

    Article  PubMed  CAS  Google Scholar 

  79. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296–302

    Article  PubMed  CAS  Google Scholar 

  80. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338: 273–7

    Article  PubMed  CAS  Google Scholar 

  81. Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999; 13(6): 1351–6

    Article  PubMed  CAS  Google Scholar 

  82. United Therapeutics Corporation. Remodulin® (treprostinil sodium) injection: product information. Research Triangle Park (NC): United Therapeutics Corporation, 2002

    Google Scholar 

  83. Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126: 420–7

    Article  PubMed  CAS  Google Scholar 

  84. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter open-label, 12 week trial. Chest 2006; 129(3): 683–8

    Article  PubMed  CAS  Google Scholar 

  85. Bettoni L, Geri A, Airo P, et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 2002; 21(3): 244–50

    Article  PubMed  CAS  Google Scholar 

  86. Baker SE, Hockman RH. Inhaled iloprost in pulmonary arterial hypertension. Ann Pharmacother 2005; 39: 1265–74

    Article  PubMed  CAS  Google Scholar 

  87. Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology 2003; 42: 191–3

    Article  PubMed  CAS  Google Scholar 

  88. Yamane K. Endothelin and collagen vascular disease: a review with special reference to Raynaud’s phenomenon and systemic sclerosis. Intern Med 1994; 33: 579–82

    Article  PubMed  CAS  Google Scholar 

  89. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132: 425–34

    PubMed  CAS  Google Scholar 

  90. Oldfield V, Lyseng-Williamson KA. Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis. Am J Cardiovasc Drugs 2006; 6(3): 189–208

    Article  PubMed  CAS  Google Scholar 

  91. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903

    Article  PubMed  CAS  Google Scholar 

  92. Hayakawa I, Shirasaki F, Hirano T, et al. Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. Rheumatol Int 2006; 26(3): 270–3

    Article  PubMed  Google Scholar 

  93. Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151(4): 851–5

    Article  PubMed  Google Scholar 

  94. Aizawa K, Hanaoka T, Kasai H, et al. Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. Hypertens Res 2006; 29(2): 123–8

    Article  PubMed  Google Scholar 

  95. Beyer S, Speich R, Fischler M, et al. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. Swiss Med Wkly 2006; 136: 114–8

    PubMed  CAS  Google Scholar 

  96. Massad MG, Powell CR, Kpodonu J, et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg 2005; 29(11): 1510–5

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

There are no sources of funding or conflicts of interest directly relevant to the preparation or content of this article.

Author information

Authors and Affiliations

  1. Rheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Cairo, Egypt

    Amira A. Shahin

Authors
  1. Amira A. Shahin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amira A. Shahin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shahin, A.A. Pulmonary Involvement in Systemic Sclerosis. Treat Respir Med 5, 429–436 (2006). https://doi.org/10.2165/00151829-200605060-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151829-200605060-00008

Keywords

Search

Navigation